{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:20:07Z","timestamp":1793125207612,"version":"4.5.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Lipoprotein(a) [Lp(a)] is an independent risk factor for cardiovascular disease due to its unique apo(a) component and its association with atherosclerosis and thrombogenesis. This meta-analysis was conducted to evaluate the effects of PCSK9 inhibitors on major adverse cardiac events (MACE) and Lp(a) levels in patients with coronary heart disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Randomized controlled trials (RCTs) were systematically searched in PubMed, the Cochrane Library, and other databases. Stata 15.1 software was used for data analysis, and a random- or fixed-effects model was selected based on inter-study heterogeneity. Egger\u2019s test was applied to detect publication bias.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 12 RCTs were included, involving 48\u2005116 patients with a mean age of 62 years, comprising 65% males and diverse ethnic backgrounds. The results showed that compared with the control group, PCSK9 inhibitors significantly reduced low-density lipoprotein cholesterol (WMD\u2005=\u2005\u22121.24\u2005mmol\/L, 95% confidence interval (CI): \u22121.28 to \u22121.20), total cholesterol, triglycerides, and Lp(a) levels while increasing high-density lipoprotein cholesterol levels. In terms of safety, there was no increased risk of adverse reactions other than injection site reactions. For MACE, PCSK9 inhibitors significantly reduced the risk of nonfatal myocardial infarction, stroke, and coronary revascularization events (RR\u2005=\u20050.87, 95% CI: 0.84\u20130.89).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>PCSK9 inhibitors not only significantly improve blood lipid profiles and reduce Lp(a) levels but also reduce the risk of MACE in patients with coronary heart disease. Therefore, PCSK9 inhibitors offer an effective and safe treatment option for these patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mca.0000000000001464","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T15:01:32Z","timestamp":1733151692000},"page":"200-210","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a meta-analysis"],"prefix":"10.1097","volume":"36","author":[{"given":"Enze","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Sixth Hospital of Wuhan, Affiliated Hospital of Jianghan University, Wuhan, Hubei Province"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macao","family":"Wan","sequence":"additional","affiliation":[{"name":"Department of the Second Clinic, The 940 Hospital of Joint Logistics Support Force of Chinese PLA, Lanzhou, Gansu Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,12,2]]},"reference":[{"key":"R1-20250331","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1161\/CIRCULATIONAHA.121.053730","article-title":"American Heart Association\u2019s life\u2019s simple 7: lifestyle recommendations, polygenic risk, and lifetime risk of coronary heart disease.","volume":"145","author":"Hasbani","year":"2022","journal-title":"Circulation"},{"key":"R2-20250331","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1139\/cjpp-2015-0193","article-title":"Adenosine plasma level correlates with homocysteine and uric acid concentrations in patients with coronary artery disease.","volume":"94","author":"Fromonot","year":"2016","journal-title":"Can J Physiol Pharmacol"},{"key":"R3-20250331","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/clinchem\/hvaa247","article-title":"Lipoprotein(a) and cardiovascular disease.","volume":"67","author":"Kamstrup","year":"2021","journal-title":"Clin Chem"},{"key":"R4-20250331","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.atherosclerosis.2017.03.021","article-title":"Significance of lipoprotein(a) levels in familial hypercholesterolemia and coronary artery disease.","volume":"260","author":"Li","year":"2017","journal-title":"Atherosclerosis"},{"key":"R5-20250331","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1161\/01.ATV.0000144010.55563.63","article-title":"Lipoprotein(a): an elusive cardiovascular risk factor.","volume":"24","author":"Berglund","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R6-20250331","doi-asserted-by":"crossref","first-page":"13638","DOI":"10.3390\/ijms222413638","article-title":"PCSK9 biology and its role in atherothrombosis.","volume":"22","author":"Barale","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R7-20250331","doi-asserted-by":"crossref","first-page":"28856","DOI":"10.1074\/jbc.M109.037085","article-title":"Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route.","volume":"284","author":"Poirier","year":"2009","journal-title":"J Biol Chem"},{"key":"R8-20250331","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.111.057406","article-title":"Gene inactivation of proprotein convertase subtilisin\/kexin type 9 reduces atherosclerosis in mice.","volume":"125","author":"Denis","year":"2012","journal-title":"Circulation"},{"key":"R9-20250331","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.tcm.2019.05.007","article-title":"The PCSK9 revolution: current status, controversies, and future directions.","volume":"30","author":"Warden","year":"2020","journal-title":"Trends Cardiovasc Med"},{"key":"R10-20250331","first-page":"e1046","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines.","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"R11-20250331","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease.","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"R12-20250331","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome.","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"R13-20250331","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"R15-20250331","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1536867X0800800102","article-title":"Metan: fixed- and random-effects meta-analysis.","volume":"8","author":"Harris","year":"2008","journal-title":"Stata J"},{"key":"R16-20250331","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/2049-3258-72-39","article-title":"Metaprop: a Stata command to perform meta-analysis of binomial data.","volume":"72","author":"Nyaga","year":"2014","journal-title":"Arch Public Health"},{"key":"R17-20250331","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis.","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"key":"R18-20250331","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test.","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"R19-20250331","first-page":"153","article-title":"Effect of early initiation of evolocumab on lipoprotein(a) in patients with acute myocardial infarction: sub-analysis of a randomized controlled trial.","volume":"9","author":"Okada","year":"2022","journal-title":"J Cardiovasc Dev Dis"},{"key":"R20-20250331","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.jcmg.2022.03.002","article-title":"Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction.","volume":"15","author":"Nicholls","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"R21-20250331","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial.","volume":"327","author":"Raber","year":"2022","journal-title":"JAMA"},{"key":"R22-20250331","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ahj.2015.03.004","article-title":"Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study.","volume":"169","author":"Kereiakes","year":"2015","journal-title":"Am Heart J"},{"key":"R23-20250331","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/clc.23112","article-title":"Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial.","volume":"41","author":"Koskinas","year":"2018","journal-title":"Clin Cardiol"},{"key":"R24-20250331","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1161\/CIRCULATIONAHA.120.046320","article-title":"Effect of evolocumab on atherogenic lipoproteins during the peri- and early postinfarction period: a placebo-controlled, randomized trial.","volume":"142","author":"Leucker","year":"2020","journal-title":"Circulation"},{"key":"R25-20250331","first-page":"22","article-title":"Influence of PCSK9 inhibitors on microcirculation function and left ventricular remodeling after PCI surgery for acute ST-segment elevation myocardial infarction.","volume":"38","author":"Xu","year":"2022","journal-title":"J Clin Cardiovasc Dis"},{"key":"R26-20250331","first-page":"2606","article-title":"Effect of alirocumab combined with rosuvastatin on coronary microcirculation, inflammation, and cardiac function in patients with acute myocardial infarction after PCI surgery.","volume":"21","author":"Zhao","year":"2022","journal-title":"J Clin Exp Med"},{"key":"R27-20250331","first-page":"907","article-title":"Effect of evolocumab combined with rosuvastatin on lipid profile and endothelial function in patients with acute myocardial infarction after PCI.","volume":"21","author":"Shen","year":"2022","journal-title":"J Diff Dis"},{"key":"R28-20250331","first-page":"830","article-title":"Effect of evolocumab combined with atorvastatin on coronary artery plaques in patients with coronary heart disease.","volume":"40","author":"Chen","year":"2021","journal-title":"Chin J New Drugs Clin Remed"},{"key":"R29-20250331","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"R30-20250331","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1016\/j.jacl.2024.03.001","article-title":"A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice.","volume":"18","author":"Koschinsky","year":"2024","journal-title":"J Clin Lipidol"},{"key":"R31-20250331","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3949\/ccjm.87a.19078","article-title":"ACC\/AHA lipid guidelines: personalized care to prevent cardiovascular disease.","volume":"87","author":"Reiter-Brennan","year":"2020","journal-title":"Cleve Clin J Med"},{"key":"R32-20250331","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s11239-016-1364-1","article-title":"PCSK9 inhibitors in the prevention of cardiovascular disease.","volume":"42","author":"Latimer","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"R33-20250331","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S2213-8587(16)30396-5","article-title":"PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study.","volume":"5","author":"Schmidt","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R34-20250331","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","article-title":"Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes.","volume":"375","author":"Ference","year":"2016","journal-title":"N Engl J Med"},{"key":"R35-20250331","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/eurjpc\/zwae018","article-title":"The use of PCSK9 inhibitors should be avoided during pregnancy: results from a Mendelian randomization study.","volume":"31","author":"Efird","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"R36-20250331","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11883-020-00881-5","article-title":"Women living with familial hypercholesterolemia: challenges and considerations surrounding their care.","volume":"22","author":"Balla","year":"2020","journal-title":"Curr Atheroscler Rep"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000001464","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T15:45:03Z","timestamp":1743435903000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000001464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,2]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000001464","relation":{},"ISSN":["0954-6928","1473-5830"],"issn-type":[{"value":"0954-6928","type":"print"},{"value":"1473-5830","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,2]]}}}